- •Family history (FH) in first degree relatives is a major risk factor, especially for premature cardiovascular disease (CVD).
- •Data are sparse on FH of differing manifestations of CVD among FDRs of patients with differing manifestations.
- •These data indicate that FH of differing ministrations of CVD produce different risks on different manifestations of CVD.
Family history (FH) of cardiovascular disease (CVD) in first degree relatives (FDR) is a major risk factor, especially for premature events. Data are sparse on FH of different manifestations of CVD among FDRs of patients with premature myocardial infarction (MI), chronic stable angina (CSA) or peripheral vascular disease (PVD).
We obtained FHs from first degree relatives (parents or siblings) of 230 consecutive patients with premature (men < 60 and women < 65 years) CVD, including 79 wth MI, 39 CSA, 51 PVD and 61 blood donors. Among 1225 parents or siblings, 421 had MI, 222 CSA, 261PVD and 321 were among blood donors.
FH of MI were 5.6% (18/321) among blood donors, 14.0% (59/421) among patients with premature MI, 14.4% (32/222) CSA, and 8.0% (21/261) PVD. (all p < 0.05). For FH of CSA the corresponding frequencies were 3.7% 5.2%, 11.3%, and 6.9%. (all p < 0.05). For PVD, the corresponding frequencies were 2.1%, 3.4%, 0.9% and 0.7%, respectively. (p = ns).
These data are compatible with the hypothesis that FH of MI, CSA and PVD are significantly different for patients with premature MI or CSA but not PVD.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to International Journal of Cardiology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring.JAMA. 2004; 291: 2204-2211
- 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The sixth joint task force of the european society of cardiology and other societies on cardiovascular disease preventionin clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).Eur. Heart J. 2016; 37: 2315-2381
- 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.Circulation. 2014; 129: S49-S73
- Sudden cardiac death.Circ. 1998; 98: 2234-2251
- Epidemiology in Medicine.Little, Brown Co. Boston, 1987
- Comparison of coronary angiographic findings in acute and chronic first presentation of ischemic heart disese.Circ. 1993; 87: 1938-1946
- Risk factors in schoolchildren associated with a family history of unheralded myocardial infarction or uncomplicated stable angina in male relatives.J. Am. Coll. Cardiol. 1994; 23: 1472-1478
- Cholesterol among children of men with myocardial infarction.Pediatrics. 1976; 58: 211-217
- Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke.Am. J. Cardiol. 1988; 62: 635-637
- Increased prevalence of the G20210A prothrombin gene variant in acute coronary syndromes without metabolic or acquired risk factors or with limited extent of disease.Eur. Heart J. 2002; 23: 26-30
- G20210A prothrombin gene polymorphism and coronary ischaemic syndromes: a phenotype-specific meta-analysis of 12 034 subjects.Heart. 2004; 90: 82-86
- Atherothrombotic disorders: new insights from hematology.Circulation. 2005; 111: 1855-1863
- Expanding the role of coagulation in arterial thrombosis: evidence from animal models using a new factor Xa inhibitor.Thromb. Haemost. 2008; 99: 651-652
- Antiplatelet agents for the treatment and prevention of atherothrombosis.Eur. Heart J. 2011; 32: 2922-2932
- Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease.Thromb. Haemost. 2016; 115: 685-711
- Prolonged endogenous fibrinolysis predicts reduced survival after acute coronary syndromes.Eur. Heart J. 2018; 39: 1086-1088
- Global risk assessment for cardiovascular disease and astute clinical judgement.Eur. Heart J. 2003; 24: 1899-1900
- Reliability of reported family history of myocardial infarction.BMJ. 1993; 307: 1528-1530
- Accuracy of proband reported family history: the NHLBI Family Heart Study (FHS).Genet. Epidemiol. 1999; 17: 141-150
- Epidemiology and prevention of coronary heart disease in families.Am. J. Med. 2000; 108: 387-395
Published online: March 15, 2021
Accepted: March 10, 2021
Received: July 19, 2020
© 2021 Elsevier B.V. All rights reserved.